A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Incyte Corporation
Incyte Corporation
Prelude Therapeutics
M.D. Anderson Cancer Center
Incyte Corporation
Incyte Corporation
Mayo Clinic
Fred Hutchinson Cancer Center
Incyte Corporation
Washington University School of Medicine
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Stanford University
H. Lee Moffitt Cancer Center and Research Institute
Brigham and Women's Hospital
University of Chicago
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Massachusetts General Hospital
Janssen Research & Development, LLC
Eli Lilly and Company
City of Hope Medical Center
AbbVie
Northwestern University
Case Comprehensive Cancer Center
University of Chicago
Fox Chase Cancer Center
Columbia University
OHSU Knight Cancer Institute
Prelude Therapeutics
Perseus Proteomics Inc.
Herlev Hospital
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Taiga Biotechnologies, Inc.
Guizhou Bailing Group Pharmaceutical Co Ltd
Medigene AG
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
University of Washington
National Cancer Institute (NCI)
Eli Lilly and Company
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fred Hutchinson Cancer Center
Ohio State University Comprehensive Cancer Center
California Cancer Consortium